El ensayo analiza un anticuerpo biespecífico frente a la Calreticulina mutada y el CD3 de los linfocitos para frenar estos trastornos hematológicos
Read moreLaminar Pharmaceuticals S.A. se complace en anunciar que el reclutamiento de pacientes para el estudio CLINGLIO (NCT04250922) se ha cerrado después de que 140 pacientes adultos se hayan reclutado con...
Read moreAugustine Therapeutics, a pioneering biotech company focused on novel treatments for neurodegenerative and cardiometabolic diseases, today announced that it has raised EUR 17 million (USD 18.5 million...
Read moreOryzon today announced that it will present final data from its Phase IIb PORTICO trial, which investigated the efficacy of vafidemstat in the treatment of Borderline Personality Disorder (BPD), as an...
Read moreThe Checkmate 8HW phase III clinical trial is evaluating the combination of nivolumab plus ipilimumab, two immunotherapy drugs, against chemotherapy as first-line treatment in patients with a subtype ...
Read moreEsta resolución afectará, de momento, a personas con enfermedad mínima residual negativa con este tipo de cáncer hematológico y facilitará su acceso a nuevos fármacos y tratamientos
Read moreNanomol Technologies es un proveedor de tecnología de sistemas de liberación controlada de fármacos y de nanoformulación de principios activos, y un laboratorio de referencia en el análisis de pa...
Read moreIt has been announced today that it they has received “Decision to grant” communications from the Japanese Patent Office (JPO) for two Japanese patent applications related to vafidemstat, Oryzon...
Read moreMetabolomics is a rapidly advancing field in biomedical research and has gained significant attention in recent years. This promising discipline involves the comprehensive analysis of metabolites in b...
Read moreEl trabajo de Viva in Vitro le ha llevado a ser pionero en el campo de la lucha contra la sepsis, donde gracias a su equipo a la vanguardia en investigación científica en las áreas de biología mol...
Read moreThe study, led by Dr. Miguel Hueso, will help create alternatives to organ donation and dialysis for the treatment of chronic diseases, and the development of new drugs.
Read moreAnnounced by the European Medicines Agency (EMA) last month, June 21, the highly selective and potent VEGFR inhibitor fruquintinib has been approved as the first novel targeted therapy in the EU for m...
Read more